Abstract
Diabetic nephropathy (DN) is the most common microvascular complication of diabetes, and also an important cause for end-stage renal disease (ESRD). Microalbuminuria is not a reliable indicator for predicting the progression of DN. Looking for early biomarkers and investigating the mechanisms of renal early lesions in DN are currently the paramount missions. Proteomics technologies have developed rapidly in recent years, and proteomics research on urine, blood and kidney tissue of DN patients may provide new hope for early diagnosis and treatment of DN. This review summarized the major technologies of proteomics and its recent progress in DN. Key words: Diabetes mellitus; Diabetic nephropathy; Proteomics
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
